NO323573B1 - Preparat inneholdende minst ett strontiumsalt, et aktivt middel, og minst ett middel valgt fra et hydrofilt middel og/eller et lipofilt middel og/eller et termal- eller mineralvann. - Google Patents

Preparat inneholdende minst ett strontiumsalt, et aktivt middel, og minst ett middel valgt fra et hydrofilt middel og/eller et lipofilt middel og/eller et termal- eller mineralvann. Download PDF

Info

Publication number
NO323573B1
NO323573B1 NO19961371A NO961371A NO323573B1 NO 323573 B1 NO323573 B1 NO 323573B1 NO 19961371 A NO19961371 A NO 19961371A NO 961371 A NO961371 A NO 961371A NO 323573 B1 NO323573 B1 NO 323573B1
Authority
NO
Norway
Prior art keywords
water
agents
preparation
skin
agent
Prior art date
Application number
NO19961371A
Other languages
English (en)
Norwegian (no)
Other versions
NO961371D0 (no
NO961371L (no
Inventor
Lionel Breton
Olivier De Lacharriere
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9504265A external-priority patent/FR2732600B1/fr
Priority claimed from FR9504268A external-priority patent/FR2732602B1/fr
Priority claimed from FR9504267A external-priority patent/FR2732601B1/fr
Priority claimed from FR9504264A external-priority patent/FR2732599B1/fr
Application filed by Oreal filed Critical Oreal
Publication of NO961371D0 publication Critical patent/NO961371D0/no
Publication of NO961371L publication Critical patent/NO961371L/no
Publication of NO323573B1 publication Critical patent/NO323573B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19961371A 1995-04-10 1996-04-03 Preparat inneholdende minst ett strontiumsalt, et aktivt middel, og minst ett middel valgt fra et hydrofilt middel og/eller et lipofilt middel og/eller et termal- eller mineralvann. NO323573B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9504265A FR2732600B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique et/ou dermatologique et composition obtenue
FR9504268A FR2732602B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique ou pharmaceutique pour traiter les prurits
FR9504267A FR2732601B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel de metal alcalino-terreux pour le traitement des rougeurs cutanees d'origine neurogene
FR9504264A FR2732599B1 (fr) 1995-04-10 1995-04-10 Utilisation de sels de metaux alcalino-terreux comme inhibiteurs de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR9510980 1995-09-20

Publications (3)

Publication Number Publication Date
NO961371D0 NO961371D0 (no) 1996-04-03
NO961371L NO961371L (no) 1996-10-11
NO323573B1 true NO323573B1 (no) 2007-06-11

Family

ID=27515606

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961371A NO323573B1 (no) 1995-04-10 1996-04-03 Preparat inneholdende minst ett strontiumsalt, et aktivt middel, og minst ett middel valgt fra et hydrofilt middel og/eller et lipofilt middel og/eller et termal- eller mineralvann.

Country Status (4)

Country Link
US (1) US5851556A (de)
EP (1) EP0737471A3 (de)
CA (1) CA2173689C (de)
NO (1) NO323573B1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US6406709B1 (en) 1997-05-29 2002-06-18 Nidaria Technology Ltd. Method for inhibiting nematocyst discharge
US6338837B1 (en) * 1997-05-29 2002-01-15 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
FR2774285B1 (fr) * 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
EP2295081B1 (de) 2001-06-26 2018-10-31 Amgen Inc. Antikörper gegen OPGL
US20030059450A1 (en) 2001-09-24 2003-03-27 Maibach Howard I. Method and topical formulation for treating skin conditions associated with aging
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
US7081247B2 (en) * 2002-05-20 2006-07-25 Nidaria Technology Ltd. Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
US20030232094A1 (en) * 2002-06-12 2003-12-18 Fuller Peter E. Composition and method for the treatment of skin irritations
US6943197B2 (en) 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
WO2004011017A1 (en) * 2002-07-31 2004-02-05 Himalayan International Institute Of Yoga Science And Philosophy Nasal irrigation solutions and methods of using same
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
EA008744B1 (ru) 2002-08-12 2007-08-31 Актавис Груп Хф. Применение соединений антагонистов кальцитонин генсвязанного пептида (cgrp) для лечения псориаза
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
CA2561082C (en) * 2003-03-27 2014-07-15 Santosolve As Anti-inflammatory treatment based on strontium compounds
ES2275218T3 (es) * 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
EP1622630B1 (de) * 2003-05-07 2012-08-29 Osteologix A/S Strontium-kombinationsbehandlung zur prophylaxe/behandlung von knorpel- und knochenzuständen
CN1993106A (zh) * 2003-06-04 2007-07-04 埃伯赛特斯公司 新的皮肤病学的组合物
DE10347824B4 (de) * 2003-10-10 2011-08-11 Lach, Hans-Joachim, Dr., 79331 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut
ES2342461T3 (es) * 2003-10-17 2010-07-07 Oy Neurofood Ab Agente de estroncio no radiactivo para tratar el cancer.
US7258875B2 (en) * 2003-12-04 2007-08-21 Chiou Consulting, Inc. Compositions and methods for topical treatment of skin infection
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
SI1732575T1 (sl) * 2004-02-26 2011-05-31 Osteologix As Spojine, ki vsebujejo stroncij, za uporabo pri preprečevanju ali zdravljenju nekrotičnih kostnih stanj
FR2872047B1 (fr) * 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
MXPA06015184A (es) * 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US20060045858A1 (en) * 2004-08-26 2006-03-02 Fuller Peter E Composition and method for reducing harmful effects of ultraviolet radiation impinging on the skin
EP1731137A1 (de) * 2005-06-08 2006-12-13 Nestec S.A. Kosmetische oder dermatologische Zusammensetzung gegen trockene und/oder empfindliche Haut
EP1642570A1 (de) 2004-10-04 2006-04-05 L'oreal Kosmetische oder dermatologische Zusammensetzung gegen trockene und/oder empfindliche Haut
BRPI0516437A (pt) * 2004-10-04 2008-09-02 Oreal E Nestec S A L utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
GB0517043D0 (en) * 2005-08-19 2005-09-28 York Pharma Plc Improvements in pharmaceutical compositions
EP3069731A1 (de) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
WO2007060381A1 (en) * 2005-11-24 2007-05-31 Santosolve As Strontium-containing compositions and their use in methods of cosmetic treatment
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions
CA2730009C (en) * 2007-07-12 2017-08-15 Whipbird Pain Relief Pty Ltd. Topical medicament
FR2919501B1 (fr) * 2007-08-02 2010-12-31 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
FR2920304B1 (fr) * 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2920305B1 (fr) 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
CA2697735C (en) * 2007-09-04 2014-02-18 L'oreal Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
AU2008274908B2 (en) * 2008-07-11 2014-08-14 Whipbird Pain Relief Pty Ltd Topical medicament
CN102369001A (zh) 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
US8409628B2 (en) * 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
KR101729096B1 (ko) 2012-03-21 2017-04-21 코스메덤 바이오사이언스, 인코퍼레이티드 통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016060626A1 (en) * 2014-10-16 2016-04-21 Geli̇şi̇m Maki̇na-Madenci̇li̇k-Mühendi̇sli̇k Ti̇c. Ve San. Ltd. Şti̇. Methods and compositions for prevention and treatment of hyperhidrosis
WO2016130686A1 (en) * 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Stable high concentration strontium compounds and formulations for topical application
FR3034667B1 (fr) * 2015-04-13 2018-09-07 Laboratoires Dermatologiques D'uriage Composition cosmetique et/ou dermatologique contre l'acne
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
US10391121B2 (en) 2017-05-03 2019-08-27 BioPharmX, Inc. Magnesium chloride composition for dermatological use
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1072355A (en) * 1964-06-17 1967-06-14 Michael Collin Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) * 1967-09-01 1970-07-07 Robert E Svigals Composition and method of treating pruritic conditions of the skin
IE35991B1 (en) * 1971-01-22 1976-07-21 Comprehensive Pharmaceuticals Improvements in or relating to the treatment of diseases of the skin and mucosa
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
EP0090798A1 (de) * 1981-10-09 1983-10-12 Ferring AB Arzneimittel auf der basis eines antagonisten der p-substanz
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
ATE69954T1 (de) * 1985-10-08 1991-12-15 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
US4735802A (en) * 1986-05-05 1988-04-05 Le Bich N Topical dermatological composition and method of treatment
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
CA2014201A1 (en) * 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5296476A (en) * 1989-09-08 1994-03-22 Henderson Esther G Skin care compositions
EP0451300B1 (de) * 1990-04-10 1994-10-26 Romuald Dr. Kowalski Bariumsulfat-kolloidale Dispersion enthaltende Zusammensetzung
FR2662607B1 (fr) * 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
JPH06509332A (ja) * 1991-07-05 1994-10-20 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
WO1993001165A2 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, compositions containing them and their use in therapy
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
DE4227203C2 (de) * 1992-08-17 1994-03-24 Kao Corp Gmbh Mittel und Verfahren zur Haarbehandlung
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
WO1994009798A1 (en) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Mixtures or complexes containing calcium and sulfate
DE4315866C1 (de) * 1993-05-12 1994-05-05 Wogepharm Gmbh Äußerliche Zubereitungen zur Therapie von Hauterkrankungen mit Photosensibilisatoren
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
BR9510488A (pt) * 1994-12-21 1998-01-13 Cosmederm Technologies Formulações e métodos para redução da irritação da pele
EP0799018A4 (de) * 1994-12-21 2000-03-29 Cosmederm Technologies Formulierungen und verfahren zur verminderung von hautirritationen
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Also Published As

Publication number Publication date
US5851556A (en) 1998-12-22
EP0737471A3 (de) 2000-12-06
NO961371D0 (no) 1996-04-03
CA2173689A1 (fr) 1996-10-11
CA2173689C (fr) 2003-10-14
NO961371L (no) 1996-10-11
EP0737471A2 (de) 1996-10-16

Similar Documents

Publication Publication Date Title
NO323573B1 (no) Preparat inneholdende minst ett strontiumsalt, et aktivt middel, og minst ett middel valgt fra et hydrofilt middel og/eller et lipofilt middel og/eller et termal- eller mineralvann.
US5972892A (en) Topical composition containing a substance P antagonist
RU2152798C1 (ru) Применение антагониста cgrp для обработки покраснений кожи неврогенного происхождения и композиция на его основе
RU2188029C2 (ru) Применение экстракта из нефотосинтезирующей нитчатой бактерии и содержащая его композиция
US5900257A (en) Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists
US5993833A (en) Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition
JP3110050B2 (ja) 敏感肌の治療における少なくとも１つのｎｏシンターゼ阻害剤の使用
US6262050B1 (en) Topical composition containing capsazepine
US6235291B1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US10052297B2 (en) L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin
US6267972B1 (en) Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists
RU2146519C1 (ru) Фармацевтическая композиция на основе антагониста вещества p
JPH10114621A (ja) 高含有量の電解質を含むｗ／ｏエマルションおよび皮膚用化粧品への使用
JP3054587B2 (ja) 化粧品組成物におけるエチレンジアミン誘導体の使用および刺激性副作用を有する成分を含有する化粧品組成物
US5895649A (en) Method for treating neurogenic red skin blotches with compositions containing TNF-alpha antagonists
US5744156A (en) Use of a substance P antagonist for the treatment of skin reddening of neurogenic origin
US5935586A (en) Therapeutic/cosmetic compositions comprising CGRP antagonists for treating disease states of the skin
US6106846A (en) Use of at least one thermal spring water from Vichy as a substance P antagonist
JP2001511782A (ja) 敏感肌のための化粧品または皮膚科用組成物における５ｈｔ▲下２▼及び５ｈｔ▲下１ｄ▼レセプターそれぞれに特異的なセロトニンアンタゴニストまたはアゴニストの使用
FR2732602A1 (fr) Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique ou pharmaceutique pour traiter les prurits
HK1165989A (en) L-serine to be use as a drug for preventing and/or treating an inflammatory response of the skin
MXPA97010475A (en) Use of at least one beta-adrenergic agonist as an antagonist of substance